Literature DB >> 1474379

Venezuelan equine encephalitis-specific immunoglobulin responses: live attenuated TC-83 versus inactivated C-84 vaccine.

R J Engler1, J A Mangiafico, P Jahrling, T G Ksiazek, M Pedrotti-Krueger, C J Peters.   

Abstract

Venezuelan equine encephalitis (VEE)-specific immunoglobulin responses to the two vaccines, TC-83 (a live attenuated vaccine) and C-84 (a formalin inactivated vaccine derived from the TC-83 strain of virus) were evaluated using an antigen and isotype-specific enzyme-linked immunoadsorbent assay (ELISA). The VEE-specific ELISA for IgG, IgG subclasses, IgA and IgM were developed and standardized using sera from vaccine-exposed and unexposed human subjects. Paired human sera (before and 28 days after immunization) were tested from laboratory workers vaccinated with either TC-83 (Group A: 20 paired sera from subjects receiving a single TC-83 vaccine and with no prior history of vaccination) or C-84 in varying schedules (Group B: 19 paired sera from subjects who had a distant vaccination history to TC-83 but no evidence of neutralizing antibody; Group C: 19 paired sera from subjects receiving their first C-84 vaccination and no prior documented history of vaccination; Group D: 15 paired sera from subjects receiving a C-84 booster vaccination with prior history of C-84 but no TC-83 exposure). Sera were all tested for viral neutralization in vitro using a Vero cell monolayer for culturing virus and establishing 80% plaque reduction for each serum tested. All pre-sera tested demonstrated no plaque reduction neutralization at a level of 80% for a dilution of 1:10. ELISA antibody titers for all pre-sera with no prior VEE exposure through vaccination or possible environmental factors were negative at a titer of 1:160 for IgM, 1:80 for IgG, IgA, and G subclasses.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1474379     DOI: 10.1002/jmv.1890380414

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  6 in total

1.  Melatonin treatment enhances the efficiency of mice immunization with Venezuelan equine encephalomyelitis virus TC-83.

Authors:  B Negrette; E Bonilla; N Valero; H Pons; J Garcia Tamayo; L Chacín-Bonilla; S Medina-Leendertz; F Añez
Journal:  Neurochem Res       Date:  2001-07       Impact factor: 3.996

2.  Liposome-antigen-nucleic acid complexes protect mice from lethal challenge with western and eastern equine encephalitis viruses.

Authors:  Aaron T Phillips; Tony Schountz; Ann M Toth; Amber B Rico; Donald L Jarvis; Ann M Powers; Ken E Olson
Journal:  J Virol       Date:  2013-11-20       Impact factor: 5.103

3.  Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus.

Authors:  Shannon S Martin; Russell R Bakken; Cathleen M Lind; Patricia Garcia; Erin Jenkins; Pamela J Glass; Michael D Parker; Mary Kate Hart; Donald L Fine
Journal:  Vaccine       Date:  2010-03-01       Impact factor: 3.641

4.  An inactivated Ross River virus vaccine is well tolerated and immunogenic in an adult population in a randomized phase 3 trial.

Authors:  Nina Wressnigg; Maikel V W van der Velden; Daniel Portsmouth; Wolfgang Draxler; Maria O'Rourke; Peter Richmond; Stephen Hall; William J H McBride; Andrew Redfern; John Aaskov; P Noel Barrett; Gerald Aichinger
Journal:  Clin Vaccine Immunol       Date:  2014-12-24

5.  Low-fidelity Venezuelan equine encephalitis virus polymerase mutants to improve live-attenuated vaccine safety and efficacy.

Authors:  Tiffany F Kautz; Mathilde Guerbois; Kamil Khanipov; Edward I Patterson; Rose M Langsjoen; Ruimei Yun; Kelsey L Warmbrod; Yuriy Fofanov; Scott C Weaver; Naomi L Forrester
Journal:  Virus Evol       Date:  2018-03-06

6.  IRES-driven expression of the capsid protein of the Venezuelan equine encephalitis virus TC-83 vaccine strain increases its attenuation and safety.

Authors:  Mathilde Guerbois; Eugenia Volkova; Naomi L Forrester; Shannan L Rossi; Ilya Frolov; Scott C Weaver
Journal:  PLoS Negl Trop Dis       Date:  2013-05-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.